CD274 and neoplasm: Currently available biomarkers to predict immunotherapy efficacy mainly include PD-L1, tumor mutational burden (TMB), and microsatellite instability/deficient mismatch repair (MSI/dMMR); however, the problem of “poor soil” is often ignored [14].